



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: October 15, 2021

Administrative Circular: 2021:38

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Introduction & Part 4 – Biological Products**

Introduction

Guidance for Influenza Vaccine Delivery in the Presence of COVID-19

This document has been updated for the 2021-22 influenza season, and includes revisions related to infection prevention and control recommendations per updated Provincial Infection Control Network (PICNet) guidance, including:

- Physical distancing or maintaining a distance of two metres between two or more people is no longer required. However, space arrangement at immunization clinics should ensure that people have enough space available to be respectful of others' personal space.
- Capacity limits for higher occupancy waiting rooms/areas are no longer required, but avoid overcrowding and ensure respectful personal space can be maintained.
- Immunizers, staff and volunteers in an immunization clinic must continue to wear a medical mask, however the use of additional PPE, such as eye protection, should be based on a point-of-care risk assessment, and per additional precautions, where indicated.

Please remove: entire document dated October, 2020

Please add: entire document dated October 15, 2021

Continuity of Immunization Services During COVID-19

This document has been updated to align with the updated PICNet guidance as described above.

Please remove: entire document dated October 27, 2020

Please add: entire document dated October 15, 2021

Page 1 of 3

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer)

- **Booster Doses:** The preferential use of Moderna COVID-19 vaccine for the booster dose has been removed; the associated footnote has been revised to indicate that while there is some evidence of a better antibody response associated with Moderna COVID-19 vaccine in this population, either COVID-19 mRNA vaccine may be used for the booster dose.
- **Adverse Events:** Content related to pericarditis and myocarditis in association with the mRNA vaccines has been updated.

Please remove page numbers: 1-6 dated October 7, 2021
Please add new page numbers: 1-6 dated October 15, 2021

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna)

- **Booster Doses:** The preferential use of Moderna COVID-19 vaccine for the booster dose has been removed; the associated footnote has been revised to indicate that while there is some evidence of a better antibody response associated with Moderna COVID-19 vaccine in this population, either COVID-19 mRNA vaccine may be used for the booster dose.
- **Adverse Events:** Content related to pericarditis and myocarditis in association with the mRNA vaccines has been updated.

Please remove page numbers: 1-5 dated October 7, 2021
Please add new page numbers: 1-5 dated October 15, 2021

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- **Booster Doses:** The preferential use of Moderna COVID-19 vaccine for the booster dose has been removed; the associated footnote has been revised to indicate that while there is some evidence of a better antibody response associated with Moderna COVID-19 vaccine in this population, either COVID-19 mRNA vaccine may be used for the booster dose.

Please remove page numbers: 1-5 dated October 7, 2021
Please add new page numbers: 1-5 dated October 15, 2021


COVID-19 Vaccine (Ad26.COVS.S [recombinant]) (Janssen Inc.)

- **Booster Doses:** The preferential use of Moderna COVID-19 vaccine for the booster dose has been removed; the associated footnote has been revised to indicate that while there is some evidence of a better antibody response associated with Moderna COVID-19 vaccine in this population, either COVID-19 mRNA vaccine may be used for the booster dose.

Please remove page numbers: 1-4 dated October 7, 2021
Please add new page numbers: 1-4 dated October 15, 2021

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division